Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis
A Loglio, P Ferenci, SCU Renteria, CYL Tham… - Journal of …, 2022 - Elsevier
The entry inhibitor bulevirtide (BLV) received conditional approval from the EMA in July
2020 for the treatment of adult patients with compensated chronic hepatitis delta. However,
the effectiveness and safety of BLV administered as monotherapy beyond 48 weeks in
difficult-to-treat patients with HDV-related cirrhosis is presently unknown. Herein, we
describe the first patients with HDV-related compensated cirrhosis who were treated with
BLV (10 mg/day as a starting dose) for up to 3 years on a compassionate use program …
2020 for the treatment of adult patients with compensated chronic hepatitis delta. However,
the effectiveness and safety of BLV administered as monotherapy beyond 48 weeks in
difficult-to-treat patients with HDV-related cirrhosis is presently unknown. Herein, we
describe the first patients with HDV-related compensated cirrhosis who were treated with
BLV (10 mg/day as a starting dose) for up to 3 years on a compassionate use program …
以上显示的是最相近的搜索结果。 查看全部搜索结果